\-\ Texto\\:\\ \ \(0\)\
\-\ urine\\ protein\\ 100mg\\/dl\ \(0\)\
\-\ urine\\ creatine\\ 56\\.2mg\\/dl\ \(0\)\
\-\ urine\\ glucose\\ 500mg\\/dl\ \(0\)\
\-\ serum\\ glucose\\ 313mg\\/dl\ \(0\)\
\-\ serum\\ creatine\\ 2\\.9mg\\/dl\ \(0\)\
\-\ patient\\ will\\ undergo\\ survellience\\ imaging\\ to\\ follow\\ lesion\\ size\\.\\ \\ imaging\\ will\\ include\\ ultrasound\\,\\ as\\ she\\ is\\ in\\ chronic\\ renal\\ insufficiency\\ from\\ her\\ dm\\ and\\ actually\\ went\\ into\\ acute\\ renal\\ failure\\ following\\ the\\ current\\ ct\\ exam\\ with\\ contrast\\.\ \(0\)\
\-\ on\\ ultrasound\\,\\ there\\ is\\ a\\ well\\-circumscribed\\,\\ partially\\ exophytic\\,\\ uniformly\\ hyperechoic\\ mass\\ measuring\\ approximately\\ 1\\.8cm\\.\\ \\ there\\ is\\ no\\ visualized\\ internal\\ blood\\ flow\\ on\\ the\\ doppler\\ image\\.\ \(0\)\
\-\ on\\ ct\\,\\ this\\ well\\-circumscribed\\ mass\\ is\\ hetergenously\\ hypodense\\ with\\ respect\\ to\\ renal\\ parenchyma\\.\\ \\ there\\ is\\ macroscopic\\ fat\\ and\\ mildly\\ enhancing\\ internal\\ soft\\ tissue\\ components\\.\\ \\ no\\ calcification\\.\ \(0\)\
\-\ angiomyolipoma\\ \\(sporadic\\)\\,\\ cholelithiasis\ \(0\)\
\-\ angiomyolipoma\ \(35\)\
\-\ renal\\ cell\\ carcinoma\\ \\(especially\\ clear\\-cell\\ variant\\)\ \(0\)\
\-\ renal\\ lipoma\ \(1\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ 68\\ y\\.o\\.\\ woman\\ with\\ dm\\ type\\ 2\\,\\ on\\ metformin\\;\\ with\\ proteinuria\\.\ \(0\)\
\-\ although\\ the\\ given\\ lesion\\ has\\ a\\ morphology\\ and\\ density\\ characteristics\\ diagnostic\\ of\\ aml\\,\\ there\\ are\\ case\\ reports\\ in\\ the\\ literature\\ of\\ cystic\\/clear\\ cell\\ renal\\ carcinomas\\ having\\ a\\ similar\\ appearance\\.\\ \\ further\\ reassuring\\ is\\ the\\ lack\\ of\\ calcification\\.\\ \\ these\\ lesions\\ should\\ be\\ followed\\,\\ as\\ they\\ can\\ hemorrhage\\ when\\ large\\.\\ \\ the\\ aml\\ is\\ a\\ hamartomatous\\ lesion\\,\\ considered\\ ostensibly\\ benign\\ although\\ sarcomatous\\ degeneration\\ has\\ rarely\\ been\\ known\\ to\\ occur\\.\\ \\ in\\ the\\ vast\\ majority\\ of\\ cases\\,\\ however\\,\\ a\\ renal\\ lesion\\ \\(partially\\ exophytic\\ 25\\%\\ of\\ the\\ time\\)\\ containing\\ macroscopic\\ fat\\,\\ hu\\ \\<\\ \\-60\\,\\ and\\ internal\\ soft\\ tissue\\ components\\ is\\ an\\ aml\\ until\\ proven\\ otherwise\\.\\ \\ there\\ is\\ a\\ 15\\%\\ association\\ with\\ tuberous\\ sclerosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.06607473840517089\ \(0\)\
\-\ aml\\:\\ 0\\.06535088234636398\ \(0\)\
\-\ creatine\\:\\ 0\\.052985886114208805\ \(0\)\
\-\ urine\\:\\ 0\\.045487175092691415\ \(0\)\
\-\ macroscopic\\:\\ 0\\.04086339622018394\ \(0\)\
\-\ dm\\:\\ 0\\.039811184134590755\ \(0\)\
\-\ exophytic\\:\\ 0\\.038269121406781424\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.037882035131153326\ \(0\)\
\-\ glucose\\:\\ 0\\.03358105280821426\ \(0\)\
\-\ well\\-circumscribed\\:\\ 0\\.033272492520721376\ \(0\)\
\-\ 56\\.2mg\\/dl\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ 500mg\\/dl\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ 313mg\\/dl\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ 2\\.9mg\\/dl\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ hetergenously\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ clear\\-cell\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ cystic\\/clear\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ ostensibly\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ \\-60\\:\\ 0\\.032409994205759185\ \(0\)\
\-\ internal\\:\\ 0\\.03159789564020704\ \(0\)\
\-\ components\\:\\ 0\\.03081283537266343\ \(0\)\
\-\ serum\\:\\ 0\\.03032478339512761\ \(0\)\
\-\ 100mg\\/dl\\:\\ 0\\.029861658983112327\ \(0\)\
\-\ survellience\\:\\ 0\\.029861658983112327\ \(0\)\
\-\ reassuring\\:\\ 0\\.029861658983112327\ \(0\)\
\-\ partially\\:\\ 0\\.0287517915112358\ \(0\)\
\-\ 1\\.8cm\\:\\ 0\\.026492943057104403\ \(0\)\
\-\ lesion\\:\\ 0\\.02559640038235963\ \(0\)\
\-\ metformin\\:\\ 0\\.025255912775408767\ \(0\)\
\-\ hamartomatous\\:\\ 0\\.02476498853781861\ \(0\)\
\-\ sarcomatous\\:\\ 0\\.024331962671434847\ \(0\)\
\-\ there\\:\\ 0\\.023377124199724056\ \(0\)\
\-\ proteinuria\\:\\ 0\\.0232743079933033\ \(0\)\
\-\ calcification\\:\\ 0\\.022807247194537715\ \(0\)\
\-\ uniformly\\:\\ 0\\.022453927289942235\ \(0\)\
\-\ vast\\:\\ 0\\.021783627448787993\ \(0\)\
\-\ although\\:\\ 0\\.02122006823953385\ \(0\)\
\-\ sporadic\\:\\ 0\\.02029294690427268\ \(0\)\
\-\ hu\\:\\ 0\\.02029294690427268\ \(0\)\
\-\ carcinomas\\:\\ 0\\.02015924233011505\ \(0\)\
\-\ respect\\:\\ 0\\.020030230124926558\ \(0\)\
\-\ will\\:\\ 0\\.019657948664552515\ \(0\)\
\-\ actually\\:\\ 0\\.019338861626753988\ \(0\)\
\-\ fat\\:\\ 0\\.019109649432953187\ \(0\)\
\-\ morphology\\:\\ 0\\.018757155725228642\ \(0\)\
\-\ ultrasound\\:\\ 0\\.018640607242693407\ \(0\)\
\-\ is\\:\\ 0\\.01860520957890636\ \(0\)\
\-\ proven\\:\\ 0\\.01788336288744511\ \(0\)\
\-\ 68\\:\\ 0\\.017813332758876387\ \(0\)\
\-\ cholelithiasis\\:\\ 0\\.017481894902279704\ \(0\)\
\-\ tuberous\\:\\ 0\\.017296487352180836\ \(0\)\
\-\ cell\\:\\ 0\\.016972358173393282\ \(0\)\
\-\ literature\\:\\ 0\\.01689709823084703\ \(0\)\
\-\ went\\:\\ 0\\.016738377010754348\ \(0\)\
\-\ hypodense\\:\\ 0\\.016738377010754348\ \(0\)\
\-\ insufficiency\\:\\ 0\\.016686957003494277\ \(0\)\
\-\ protein\\:\\ 0\\.016120226562952884\ \(0\)\
\-\ undergo\\:\\ 0\\.015949197093706954\ \(0\)\
\-\ degeneration\\:\\ 0\\.015949197093706954\ \(0\)\
\-\ containing\\:\\ 0\\.015949197093706954\ \(0\)\
\-\ hyperechoic\\:\\ 0\\.015706704565060643\ \(0\)\
\-\ characteristics\\:\\ 0\\.015629302325362728\ \(0\)\
\-\ majority\\:\\ 0\\.015442639364431025\ \(0\)\
\-\ soft\\:\\ 0\\.015300932088187868\ \(0\)\
\-\ association\\:\\ 0\\.015264997536229527\ \(0\)\
\-\ doppler\\:\\ 0\\.015196276458978964\ \(0\)\
\-\ rarely\\:\\ 0\\.015062571884821335\ \(0\)\
\-\ variant\\:\\ 0\\.014965390792659\ \(0\)\
\-\ tissue\\:\\ 0\\.014892802856269071\ \(0\)\
\-\ imaging\\:\\ 0\\.01472113106217355\ \(0\)\
\-\ current\\:\\ 0\\.014718139958066472\ \(0\)\
\-\ lipoma\\:\\ 0\\.01468837080279949\ \(0\)\
\-\ \\%\\:\\ 0\\.014656772304014761\ \(0\)\
\-\ having\\:\\ 0\\.014430769469649796\ \(0\)\
\-\ lack\\:\\ 0\\.014295090951504757\ \(0\)\
\-\ \\,\\:\\ 0\\.013933606313389791\ \(0\)\
\-\ until\\:\\ 0\\.013797512466689454\ \(0\)\
\-\ parenchyma\\:\\ 0\\.013380031953649518\ \(0\)\
\-\ mildly\\:\\ 0\\.013380031953649518\ \(0\)\
\-\ especially\\:\\ 0\\.01293088624050905\ \(0\)\
\-\ visualized\\:\\ 0\\.012716662313582667\ \(0\)\
\-\ 25\\:\\ 0\\.012699361243592179\ \(0\)\
\-\ considered\\:\\ 0\\.012682141209355319\ \(0\)\
\-\ reports\\:\\ 0\\.012665001455289836\ \(0\)\
\-\ measuring\\:\\ 0\\.012563807803120388\ \(0\)\
\-\ 15\\:\\ 0\\.012530686222449924\ \(0\)\
\-\ diagnostic\\:\\ 0\\.012449164687544327\ \(0\)\
\-\ similar\\:\\ 0\\.012322377275517972\ \(0\)\
\-\ failure\\:\\ 0\\.012306831922174143\ \(0\)\
\-\ \\<\\:\\ 0\\.012125240909933053\ \(0\)\
\-\ has\\:\\ 0\\.011799264488928514\ \(0\)\
\-\ occur\\:\\ 0\\.011786936135226245\ \(0\)\
\-\ they\\:\\ 0\\.011319654876791567\ \(0\)\
\-\ otherwise\\:\\ 0\\.011284247181714504\ \(0\)\
\-\ sclerosis\\:\\ 0\\.011284247181714504\ \(0\)\
\-\ benign\\:\\ 0\\.010842096937622064\ \(0\)\
\-\ given\\:\\ 0\\.010769905854839494\ \(0\)\
\-\ on\\:\\ 0\\.010645456064197471\ \(0\)\
\-\ type\\:\\ 0\\.010590530251275406\ \(0\)\
\-\ size\\:\\ 0\\.010532631880069013\ \(0\)\
\-\ followed\\:\\ 0\\.010532631880069013\ \(0\)\
\-\ cases\\:\\ 0\\.01046621641169534\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.010456825677117778\ \(0\)\
\-\ flow\\:\\ 0\\.010382551017862191\ \(0\)\
\-\ density\\:\\ 0\\.010336879988455732\ \(0\)\
\-\ should\\:\\ 0\\.01001547258047353\ \(0\)\
\-\ further\\:\\ 0\\.00999060346250095\ \(0\)\
\-\ follow\\:\\ 0\\.009982350999803066\ \(0\)\
\-\ known\\:\\ 0\\.009941364281116983\ \(0\)\
\-\ enhancing\\:\\ 0\\.009852770341488085\ \(0\)\
\-\ image\\:\\ 0\\.009813195464329415\ \(0\)\
\-\ approximately\\:\\ 0\\.00971991847998376\ \(0\)\
\-\ as\\:\\ 0\\.009504246366868587\ \(0\)\
\-\ her\\:\\ 0\\.009446366391488733\ \(0\)\
\-\ y\\.o\\:\\ 0\\.009067571443333457\ \(0\)\
\-\ when\\:\\ 0\\.008997541314764726\ \(0\)\
\-\ appearance\\:\\ 0\\.008984950649759712\ \(0\)\
\-\ following\\:\\ 0\\.00891646234154834\ \(0\)\
\-\ carcinoma\\:\\ 0\\.008904145845646567\ \(0\)\
\-\ time\\:\\ 0\\.008873533923673944\ \(0\)\
\-\ chronic\\:\\ 0\\.008849226591569852\ \(0\)\
\-\ she\\:\\ 0\\.008819066696522692\ \(0\)\
\-\ include\\:\\ 0\\.008813064294228996\ \(0\)\
\-\ ct\\:\\ 0\\.00878899745141208\ \(0\)\
\-\ a\\:\\ 0\\.008748525040116206\ \(0\)\
\-\ however\\:\\ 0\\.008747676674989229\ \(0\)\
\-\ mass\\:\\ 0\\.008738683874614446\ \(0\)\
\-\ blood\\:\\ 0\\.008575040707754777\ \(0\)\
\-\ been\\:\\ 0\\.008547040034794085\ \(0\)\
\-\ lesions\\:\\ 0\\.00841014892038216\ \(0\)\
\-\ these\\:\\ 0\\.008175899602786177\ \(0\)\
\-\ \\(\\:\\ 0\\.007967224921807285\ \(0\)\
\-\ metastatic\\:\\ 0\\.00790849045447092\ \(0\)\
\-\ \\)\\:\\ 0\\.00786990101595557\ \(0\)\
\-\ acute\\:\\ 0\\.007756909298185644\ \(0\)\
\-\ into\\:\\ 0\\.007475464588087157\ \(0\)\
\-\ \\;\\:\\ 0\\.007446401428134536\ \(0\)\
\-\ woman\\:\\ 0\\.00725699613047392\ \(0\)\
\-\ can\\:\\ 0\\.007125817472312756\ \(0\)\
\-\ contrast\\:\\ 0\\.007032263554440829\ \(0\)\
\-\ exam\\:\\ 0\\.006901595367461537\ \(0\)\
\-\ case\\:\\ 0\\.006873178062012025\ \(0\)\
\-\ large\\:\\ 0\\.006869641293496617\ \(0\)\
\-\ 2\\:\\ 0\\.006765090060700537\ \(0\)\
\-\ no\\:\\ 0\\.00632679522576325\ \(0\)\
\-\ disease\\:\\ 0\\.0051350644897636185\ \(0\)\
\-\ be\\:\\ 0\\.004844693835823269\ \(0\)\
\-\ to\\:\\ 0\\.00471031001959176\ \(0\)\
\-\ from\\:\\ 0\\.004656013651302251\ \(0\)\
\-\ in\\:\\ 0\\.0046477635677234005\ \(0\)\
\-\ an\\:\\ 0\\.00434435611869386\ \(0\)\
\-\ are\\:\\ 0\\.00428262453135883\ \(0\)\
\-\ the\\:\\ 0\\.004066155432459582\ \(0\)\
\-\ this\\:\\ 0\\.003533592696007842\ \(0\)\
\-\ patient\\:\\ 0\\.0031492350401337793\ \(0\)\
\-\ and\\:\\ 0\\.0026471912607679182\ \(0\)\
\-\ with\\:\\ 0\\.0021508120604759144\ \(0\)\
\-\ of\\:\\ 0\\.0021416139852571403\ \(0\)\
\-\ \\.\\:\\ 0\\.001957695005368361\ \(0\)\
